Search | Clinical Trials Finder

Conditions: Venous Thromboses, Venous Stasis
Interventions: OsciPulse system, Reference Therapy 1, Refence Therapy 2; Device
Lead sponsor: OsciFlex LLC; Industry
Eligibility: 40 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions: Method(s)1 Attribution, Method(s)2 Attribution,; Drug
Lead sponsor: DR. DIANE CHISESI NFS. MD. PHD.; Other
Eligibility: 44 Years to 59 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Information Dissemination, Interprofessional Relations
Interventions: Discharge communication software, Usual care discharge process; Device · Other
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions: Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Hepatitis C
Interventions: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Pain
Interventions: 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Head Lice, Pediculosis Capitis
Interventions: X92001752, RID Super Max Solution, Nix Crème, Pouxit Végétal; Device · Drug
Lead sponsor: Oystershell NV; Industry
Eligibility: 1 Year and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Healthy
Interventions: Lasmiditan, Propranolol; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Dementia Severe
Interventions: AMUSED, Reading Aloud; Behavioral
Lead sponsor: Alaine E Hernandez, PhD; Other
Eligibility: 65 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Cynthiana, Kentucky • Danville, Kentucky • Lexington, Kentucky + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Experimental: Arm A: DRL_RI, Arm B: Rituxan®/Mabthera®; Biological
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 26
States / cities: Phoenix, Arizona • Palmdale, California • Upland, California + 18 more

Conditions: Healthy
Interventions: Fentanyl; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Prostate Cancer
Interventions: Fleet Enema, Aixplorer® ShearWave Elastography (SWE™), Pre-surgery Ultrasound, Prostatectomy; Other · Device · Diagnostic Test + 1 more
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Subjects
Interventions: Quizartinib, Rufinamide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Caries
Interventions: 0 ppm F, 250 ppm F as MFP, 1100 ppm as MFP, 2800 ppm F as MFP; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Major Depressive Disorder
Interventions: Vortioxetine, Duloxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 38
States / cities: Beverly Hills, California • Irvine, California • Santa Ana, California + 35 more

Conditions: Sleep Disordered Breathing (SDB), Sleep Apnea
Interventions: SSAM, Polysomnography, EnsoSleep; Device · Diagnostic Test
Lead sponsor: Pathway Medtech, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Burlingame, California • Irvine, California • La Jolla, California

Conditions: Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions: NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2); Drug
Lead sponsor: NeuroPro Therapeutics, Inc.; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Acne Vulgaris
Interventions: Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 14
States / cities: Encino, California • Fremont, California • Brandon, Florida + 8 more

Conditions: Opioid Use Disorder
Interventions: RBP-6000, SUBOXONE Sublingual Film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Molnupiravir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Multiple Sclerosis
Interventions: tDCS Administration during MRI, Remotely-supervised Daily tDCS Administration, Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 79 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Refractory Chronic Cough
Interventions: 3 mg NOC-100 (via nebulizer), 1 mg NOC-110 (via DPI) [1x 1 mg capsule], 3 mg NOC-110 (via DPI), Placebo (via DPI), 6 mg NOC-110 (via DPI), Placebo (via DPI) [2x Placebo capsules]; Drug
Lead sponsor: Nocion Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 3
States / cities: Phoenix, Arizona • Leesburg, Florida • Winter Park, Florida

Conditions: Schizophrenia
Interventions: vabicaserin, risperidone, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more

Conditions: Postmenopause
Interventions: Premarin/MPA, Provera 10 mg; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 35 Years to 70 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

Value of Technology to Transfer Discharge Information

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

A Clinical Trial to Evaluate Efficacy and Safety of a New Suffocating Head Lice Product.

A Study of Lasmiditan and Propranolol in Healthy Participants

A Multimodal Music Therapy Intervention for Engaging Persons With Severe Dementia

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants

Feasibility Study of Ultrasound Elastography Detecting Prostate Cancer

Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects

Salivary Fluoride Clearance

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

Detection of Sleep Stages and Arousals Using Neural Network Classifiers

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)

Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Study Evaluating Vabicaserin in Subjects With Schizophrenia

Study Comparing Premarin®/MPA, PREMPRO® and Provera® in Healthy Postmenopausal Women